1. P812: LONG-TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS. (23rd June 2022) Authors: Kulasekararaj, A.; Brodsky, R.; Griffin, M.; Kulagin, A.; Ogawa, M.; Wang, J.; Mujeebuddin, A.; Nishimura, J.-I.; Peffault de Latour, R.; Szer, J.; Lee, J. W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 706 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION. (23rd June 2022) Authors: Röth, A.; Egyed, M.; Ichikawa, S.; Ito, Y.; Kim, J. S.; Nagy, Z.; Obara, N.; Panse, J.; Schrezenmeier, H.; Sica, S.; Soret, J.; Usuki, K.; Yoon, S.-S.; Benkali, K.; Buri, M.; Lundberg, P.; Patel, H.; Shinomiya, K.; Sreckovic, S.; Nishimura, J.-I. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB1934: REAL-WORLD OUTCOMES OF ECULIZUMAB TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINUREA: A SYSTEMATIC LITERATURE REVIEW AND EVIDENCE SYNTHESIS. (23rd June 2022) Authors: Nishimura, J.-I.; Popoff, E.; Cheung, A.; Wang, A.; Tomazos, I.; Szer, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1810 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗